The lysosomal degradation pathway of autophagy has a crucial role in defence against infection, neurodegenerative disorders, cancer and ageing. Accordingly, agents that induce autophagy may have broad therapeutic applications. One approach to developing such agents is to exploit autophagy manipulation strategies used by microbial virulence factors.
Autophagy functions in metazoans in cellular and tissue homeostasis, physiology, development, and protection against disease, and abnormalities in autophagy may contribute to many different pathophysiological conditions 1, 2 . Thus, strategies that augment autophagy may prevent or treat human disease 3 . Although some drugs in clinical use are capable of augmenting autophagy, these compounds exert pleiotropic effects, revealing an unmet need to develop specific inducers of autophagy.
We sought to develop a specific autophagy-inducing agent with a potentially wide range of therapeutic effects. As viruses often provide key insights into the functionally important domains of host proteins, we investigated the molecular determinants governing the interaction between beclin 1, an essential autophagy protein in the class III phosphatidylinositol-3-OH kinase (PI(3)K) complex involved in autophagic vesicle nucleation 4 , and the HIV-1 virulence factor, Nef 5 . These investigations led us to identify a Nef-interacting sequence of beclin 1 that is necessary and sufficient for autophagy induction and which provided the basis for the development of an autophagy-inducing peptide drug that has benefits in the clearance of polyglutamine expansion protein aggregates and the treatment of infectious diseases.
The HIV-1 Nef-interacting domain of beclin 1
HIV-1 Nef acts as an antiautophagic maturation factor through interaction with beclin 1 (ref. 5) and is required for efficient viral replication and AIDS pathogenicity. To map the Nef-interacting domain of beclin 1, we co-transfected Flag-tagged beclin 1 deletion mutants (amino acids 1-377, 141-450 and 257-450) with haemagglutinin (HA)-tagged Nef. These Flag-beclin 1 mutants immunoprecipitated with Nef-HA ( Supplementary Fig. 1a , b), indicating that amino acids 257-337, a region in the beclin 1 evolutionarily conserved domain (ECD) 6, 7 , are involved in Nef binding. Studies with beclin 1 mutants containing deletions in the ECD revealed that amino acids 267-299 were required for binding to Nef ( Supplementary Fig. 1c ). Deletion of amino acids 267-284 weakened binding to Nef more than deletion of amino acids 285-299 ( Fig. 1a) but had no effect on binding to Vps34 (also called PIK3C3) ( Supplementary Fig. 2a ), the class III PI(3)K that interacts with the beclin 1 ECD 6 . Thus, beclin 1 amino acids 267-284 in the ECD are crucial for beclin 1 binding to Nef. These residues are also required for the autophagy function of beclin 1; Flagbeclin 1, but not Flag-beclin 1(D267-284), increased starvationinduced autophagy in MCF7 cells (that express low amounts of endogenous beclin 1 (ref. 8)) as measured by quantification of GFP-LC3 dots, a marker of autophagosomes 9 ( Fig. 1b) .
Tat-beclin 1 is an autophagy-inducing peptide
We hypothesized that amino acids 267-284 of beclin 1 may be sufficient to induce autophagy, so we designed a cell-permeable peptide, Tatbeclin 1, composed of the HIV-1 Tat protein transduction domain (PTD) 10 attached via a diglycine linker to 18 amino acids derived from amino acids 267-284 of beclin 1 (Fig. 1c) . Three substitutions were made (in residues not conserved in all Atg6/beclin 1 orthologues, Supplementary Fig. 3 ) to enhance peptide solubility. These substitutions had no effect on binding of full-length beclin 1 to Nef (Supplementary Fig. 1d ). The 18 amino acids derived from beclin 1 in Tat-beclin 1 were randomly shuffled to generate a control peptide (Tatscrambled, Fig. 1c ). Circular dichroism spectra of Tat-beclin 1 and Tatscrambled revealed that both peptides are random coils ( Supplementary Fig. 4 ), which is consistent with corresponding structural elements of Tat 11 and the beclin 1 ECD 7 . We used several complementary methods 9 to demonstrate that the Tat-beclin 1 peptide induces autophagy. Treatment with Tatbeclin 1, but not Tat-scrambled, resulted in a dose-dependent decrease in amounts of p62, a selective autophagy substrate, and a dose-dependent conversion of the non-lipidated form of LC3, LC3-I, to the lipidated, autophagosome-associated form of LC3, LC3-II, in multiple cell lines and primary murine embryonic fibroblasts (MEFs) (Fig. 1d and Supplementary Fig. 5) . A peptide consisting of the HIV Tat PTD fused to the wild-type sequence of beclin 1 amino acids 267-284 was not soluble in saline-based solutions; however, when dissolved in H 2 O, it induced LC3-II conversion and p62 degradation more efficiently than Tat-beclin 1 ( Supplementary Fig. 6 ). The previously reported Tat-vFLIP a2 peptide 12 , derived from viral-encoded FLICE inhibitory protein, induced autophagy as efficiently as Tatbeclin 1 ( Supplementary Fig. 7 ). In HeLa/GFP-LC3 cells 13 , Tat-beclin 1 increased GFP-LC3 dot numbers (autophagosomes) 27-fold (Fig. 1e, f) . Ultrastructurally, increased numbers of autophagosomes and autolysosomes were observed in Tat-beclin 1-treated HeLa cells (Supplementary Fig. 8a ). Bafilomycin A1, an inhibitor of autophagosomal/lysosomal fusion, further increased amounts of LC3-II and p62 in Tat-beclin 1-treated HeLa and COS-7 cells, indicating enhanced autophagic flux (Supplementary Fig. 8b ). The magnitude of change in p62 upon bafilomycin A1 treatment was similar in Tat-beclin 1-treated cells to that observed in cells subjected to starvation (Supplementary Fig. 9 ). Long-lived protein degradation was increased in Tat-beclin 1-treated cells, and partially blocked by 3-methyladenine (3-MA), an autophagy inhibitor that targets class III PI(3)K (ref.
3) (Supplementary Fig. 8c ).
Together, these results indicate that the Tat-beclin 1 peptide induces a complete cellular autophagy response. This response involves the canonical autophagy pathway, as short interfering RNA (siRNA) knockdown of two essential autophagy genes, BECN1 (involved in vesicle nucleation) and ATG7 (involved in the protein conjugation system) ( Supplementary Fig. 10 ), decreased the number of Tat-beclin 1-induced autophagosomes (Fig. 1g) . The upstream signalling events in Tat-beclin 1-induced autophagy might be partially distinct from those in starvation-induced autophagy, as additive effects were observed in cells simultaneously treated with Tat-beclin 1 and subjected to starvation ( Supplementary Fig. 11) .
A sequence alignment of Atg6/beclin 1 orthologues revealed two conserved aromatic residues within amino acids 267-284: F270 and F274 ( Supplementary Fig. 3 ). In the beclin 1 ECD structure (a domain that binds to liposomes in vitro 7 at the yellow-coloured site in Fig. 1h ), these aromatic side chains intercalate in the hydrophobic core in a T-shaped geometry and help to position the intervening residues in a surface-exposed loop. They are predicted to have a similar function in the Tat-beclin 1 peptide, thus contributing to its structural stability (Fig. 1h) . Consistent with this prediction, mutation of either of these two residues to serine (F270S and F274S) abrogated the peptide's autophagy-inducing activity (Fig. 1i) . Moreover, the subcellular localization of Tat-beclin 1(F270S) lacked the discrete punctate appearance of Tat-beclin 1 ( Supplementary Fig. 12 ).
Tat-beclin 1 binds the autophagy inhibitor GAPR-1
We performed biochemical analyses to identify cellular proteins that bind to a biotin-conjugated form of the autophagy-inducing Tatbeclin 1 peptide. A protein that migrated at a molecular mass between 15 and 20 kDa bound to biotin-Tat-beclin 1 but not biotin-Tatscrambled ( Supplementary Fig. 13 ). This band was identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as Golgi-associated plant pathogenesis-related protein 1 (GAPR-1) (also known as GLIPR2), a protein that associates with lipid rafts at the cytosolic leaflet of the Golgi membrane 14 . Endogenous GAPR-1, but not Vps34, immunoprecipitated with the biotin-Tat-beclin 1 peptide ( Fig. 2a and Supplementary Fig. 2b ). Flag-beclin 1, but not Flagbeclin 1(D267-284), immunoprecipitated with GAPR-1 in HeLa cells expressing GAPR-1-Myc and Flag-beclin 1 (Fig. 2b) . Thus, amino acids 267-284 of beclin 1 are necessary and sufficient for beclin 1 to bind GAPR-1. Biotin conjugates of mutant peptides defective in autophagy induction (Fig. 1i) failed to bind to GAPR-1 (Fig. 2a) .
To evaluate the function of GAPR-1 in autophagy, we treated HeLa/GFP-LC3 cells with siRNAs directed against GAPR-1 (Supplementary Fig. 14a) . Knockdown of GAPR-1 led to increased numbers of autophagosomes in both Tat-scrambled-and Tat-beclin 1-treated RESEARCH ARTICLE cells (Fig. 2c ). This was due to an increase in autophagic flux, rather than a block in autophagosome maturation, as numbers of autophagosomes increased further upon bafilomycin A1 treatment. (We infer that the number of lysosomes available for autophagolysosomal fusion may be rate-limiting, as absolute numbers of autolysosomes did not increase ( Supplementary Fig. 15 ).) Taken together, our data indicate that GAPR-1 is a beclin 1-interacting protein that negatively regulates autophagy.
We examined the subcellular localization of endogenous beclin 1 after Tat-beclin 1 treatment, GAPR-1 overexpression or GAPR-1 knockdown ( Fig. 2d and Supplementary Fig. 14) . Beclin 1 levels were not affected by GAPR-1 overexpression or GAPR-1 knockdown. In control-transfected HeLa cells treated with control peptide, beclin 1 staining predominantly overlapped with a Golgi apparatus marker (GM130). After Tat-beclin 1 peptide treatment, beclin 1 redistributed to non-Golgi subcellular compartments; beclin 1 demonstrated colabelling with markers for organelles such as endosomes (EEA1), lysosomes (LAMP1) and endoplasmic reticulum (PD1) (data not shown). In addition, we observed a significant increase in the number of punctate structures containing WIPI2 ( Fig. 2f and Supplementary   Fig. 16 ), a mammalian protein that binds to phosphatidylinositol 3-phosphate at the site of early autophagosomal structures 15 . In HeLa cells expressing GAPR-1-Myc, Tat-beclin 1 treatment resulted in less redistribution of beclin 1 to non-Golgi sites and decreased WIPI2 puncta. Conversely, even in the absence of Tat-beclin 1 peptide, GAPR-1 siRNA knockdown led to an increase in beclin 1 redistribution to non-Golgi sites and in WIPI2 puncta.
To confirm that Tat-beclin 1 induced beclin 1 localization to nonGolgi sites, we measured the amounts of beclin 1 in purified HeLa cell Golgi fractions after peptide treatment (Fig. 2e) . In control-transfected cells, treatment with Tat-beclin 1 led to the disappearance of beclin 1 in the Golgi fraction, whereas in cells expressing GAPR-1-Myc, increased amounts of beclin 1 were detected in the Golgi fraction, which were only minimally decreased by treatment with Tat-beclin 1. Thus, GAPR-1 may function to tether beclin 1 in the Golgi apparatus (where it is inactive in autophagy), and the Tat-beclin 1 peptide may promote the release of beclin 1 from the Golgi, resulting in enhanced early autophagosome formation. Other unknown mechanisms may also contribute to the autophagy-inducing activity of Tat-beclin 1. 
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Tat-beclin 1 has beneficial effects in vitro
Our discovery that Tat-beclin 1 is an inducer of autophagy led us to explore whether it may represent a candidate therapeutic agent for neurodegenerative diseases and infectious diseases. Pharmacological activation of autophagy reduces levels of soluble and aggregated proteins involved in polyglutamine repeat expansion disorders (such as Huntington's disease, the spinocerebellar ataxias, and synucleinopathies and tauopathies) and reduces their cytotoxicity in vitro and neurotoxicity in mouse or Drosophila models 3, 16 . We therefore investigated whether Tat-beclin 1 peptide treatment decreases aggregates of a model polyglutamine expansion protein (htt103Q) derived from exon 1 of human mutant huntingtin protein 17 . In HeLa cells expressing doxycyline-repressible CFP fused to htt103Q (ref. 17 ), Tat-beclin 1 treatment did not affect the number of large (.1 mm) CFP-htt103Q aggregates (data not shown), consistent with previous reports that autophagy does not clear large protein aggregates 16 . In contrast, Tat-beclin 1 treatment decreased the number of small (,1 mm) CFP-htt103Q aggregates as efficiently as doxycycline ( Fig. 3a and Supplementary Fig. 17 ). (Similar results were obtained using Torin1, an inhibitor of mTOR that induces autophagy 3 ( Supplementary Fig. 18 ).) We confirmed our findings biochemically using a filter trap assay that separates large protein aggregates, small protein aggregates and soluble proteins; Tat-beclin 1 decreased small htt103Q aggregates to a similar degree as doxycycline (Fig. 3b) . Tatbeclin 1 peptide also decreased amounts of soluble htt103Q protein, indicating that Tat-beclin 1 can clear the pre-aggregated and small aggregated form of htt103Q protein. Further studies are required to determine whether Tat-beclin 1 peptide is effective in animal models of full-length disease-causing polyglutamine expansion proteins.
Autophagy genes have beneficial effects in animal models of certain viral and intracellular bacterial infections, and autophagy-inducing agents (such as rapamycin and vitamin D) inhibit HIV replication in primary human monocyte-derived macrophages (MDMs) 3 . We therefore investigated the effects of the Tat-beclin 1 peptide on the replication of three positive-stranded RNA viruses (Sindbis virus (SINV), chikungunya virus (CHIKV), West Nile virus (WNV)), HIV-1, and the intracellular bacterium, Listeria monocytogenes. Tat-beclin 1 treatment (10 mM for 4 h beginning 4 h post-infection) reduced SINV, CHIKV and WNV titres 10-50-fold in HeLa cells (Fig. 3c) . Tat-beclin 1 treatment reduced CHIKV replication even if administered 24 h post-infection ( Supplementary Fig. 19 ). Tat-beclin 1-mediated reduction in viral titres was not due to peptide cytotoxicity, as the peptide did not kill uninfected cells (Supplementary Fig.  20a ) and there was increased, rather than decreased, cell survival in Tat-beclin 1 peptide-treated virally infected cells (data not shown). Thus, the decreased viral titres probably reflect xenophagic degradation of the viruses or other antiviral effects of increased autophagy.
Tat-beclin 1 peptide decreased the intracellular survival of L. monocytogenes in primary murine bone-marrow-derived macrophages (BMDMs) (Fig. 3d) . We used a strain of L. monocytogenes lacking the autophagy evasion protein, ActA 18 , and a dose of the peptide (10 mM for 2 h) that is non-toxic to uninfected BMDMs ( Supplementary Fig. 20b, c) . This antibacterial effect was decreased in BMDMs derived from Atg5 flox/flox lysozymeM-Cre mice 19 that had decreased Atg5 expression and decreased Tat-beclin 1-induced autophagy ( Supplementary Fig. 21 ).
Tat-beclin 1 markedly inhibited HIV-1 replication in primary human MDMs. Using an established pre-treatment model 20, 21 , we observed a dose-dependent inhibition of HIV p24 antigen release in MDMs cultured in the presence of non-toxic concentrations (0.5, 1, 2.5, and 5 mM) of Tat-beclin 1, with nearly undetectable antigen levels in cells treated daily with 5 mM Tat-beclin 1 peptide (Fig. 3e and Supplementary Fig. 22 ). The magnitude of inhibition of HIV-1 replication was similar to that observed with the mTOR inhibitor rapamycin, which also induces autophagy (Supplementary Fig. 23 ). Tat-beclin 1 peptide-mediated inhibition of HIV-1 replication appeared to occur via the canonical autophagy pathway, as short hairpin RNA (shRNA) knockdown of the essential autophagy gene, ATG5 (Supplementary Fig. 22c ), decreased Tat-beclin 1-induced 
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autophagy (as assessed by LC3 lipidation (Fig. 3g) ) and completely abrogated the antiviral effects of Tat-beclin 1 treatment (Fig. 3f) without any decrease in cell survival (Supplementary Fig. 22d ).
Tat-beclin 1 induces autophagy in vivo
To show that Tat-beclin 1 induces autophagy in vivo, we examined numbers of autophagosomes in tissues of mice that transgenically express GFP-LC3 (ref. 22 ) and compared two forms of Tat-beclin 1, including the sequence in Fig. 1c composed of L-amino acids, and a retro-inverso sequence of Tat-beclin 1 composed of D-amino acids, which is predicted to be more resistant to proteolytic degradation 23 . Significantly more GFP-LC3 dots (autophagosomes) were observed in skeletal muscle, cardiac muscle and pancreas after intraperitoneal (i.p.) treatment with the L-or D-form of Tat-beclin 1 as compared to the L-form of Tat-scrambled or D-form of Tat (Fig. 4a and Supplementary Fig. 24) . By imaging tissue stained with streptavidin linked to an infrared dye, we confirmed that biotin-conjugated Tatbeclin 1 enters muscle cells (Supplementary Fig. 25 ). In 5-day-old suckling mouse brains, treatment with the D-form (but not L-form) of Tat-beclin 1 reduced p62 levels (Fig. 4b) . Thus, Tat-beclin 1 can induce autophagy in peripheral tissues in adult mice as well as in the central nervous system of neonatal mice.
Daily Tat-beclin 1 peptide treatment was well-tolerated in both neonatal and adult mice. During a 2-week course, neonatal mice had normal weight gain, motor activity, renal function and clinical status as well as normal histology of the heart, kidney, brain and liver ( Supplementary Fig. 26 and Supplementary Table 1 , and data not shown). These parameters, as well as hepatic and haematological function, were also normal in Tat-beclin 1 peptide-treated 3-month-old mice (Supplementary Table 1 and data not shown).
Tat-beclin 1 improves clinical outcomes
We investigated the effect of the Tat-beclin 1 peptide on the outcome of neonatal infection with CHIKV and WNV. After subcutaneous (s.c.) inoculation with CHIKV, neonatal mice develop lethal infection similar to that observed in human neonates, characterized by flaccid paralysis and abundant viral replication in muscle, skin and joints 24 . Tat-beclin 1 peptide treatment (15 mg kg 21 i.p. daily, L-form, beginning one day post-infection) reduced viral titres at day 4 and day 6 in the soleus and vastus lateralis muscles ( Supplementary Fig. 27a ) and decreased clinical paralysis (data not shown). In neonatal GFP-LC3 transgenic mice, autophagosomes were increased in muscle, including in cells that expressed CHIKV E2 envelope glycoprotein (Supplementary Fig. 27b) . Importantly, Tat-beclin 1 treatment reduced mortality of neonatal mice infected with CHIKV; 100% of mice treated with control Tat-scrambled peptide died as compared to 62.5% of mice treated with Tat-beclin 1 peptide (Fig. 4c) .
Arbovirus infections of the central nervous system (CNS) in human infants are often lethal and have no effective treatment 25, 26 . We evaluated the effects of the Tat-beclin 1 peptide (D-form) on clinical outcome in a neonatal mouse model of WNV CNS infection. Tat-beclin 1 peptide treatment increased brain viral titres at day 2 post-infection, but resulted in more than a 1,000-fold reduction in brain viral titres by day 6 post-infection ( Supplementary  Fig. 28 ). The brains of control Tat peptide (D-form)-treated mice had higher levels of viral antigen staining at day 4 and day 6 postinfection, more neuropathology, and more cell death than those of Tat-beclin 1 peptide-treated mice (Fig. 4d, e and data not shown) . Tat-beclin 1 peptide treatment also significantly reduced mortality in WNV-infected mice (Fig. 4f) . (The antiviral effects of Tat-beclin 1 in vivo may be autophagy-dependent, as CNS viral titres were not reduced in Tat-beclin 1 peptide-treated mice with monoallelic deletion of Becn1 (Fig. 4g) .) Taken together, our findings demonstrate that the Tat-beclin 1 peptide improves the clinical outcome of mice with CNS WNV infection.
Discussion
By mapping the domain of beclin 1 targeted by the HIV-1 pathogenicity protein, Nef, we identified a functionally important region of beclin 1, leading to the synthesis of a cell-permeable autophagyinducing peptide and the discovery of a negative regulator of autophagy, GAPR-1. The autophagy-inducing activity of the peptide was associated with clearance of small polyglutamine expansion protein aggregates, reduced titres of several positive-stranded RNA viruses, decreased intracellular survival of the bacterium, L. monocytogenes, inhibition of HIV-1 replication in human macrophages, and a reduction in the mortality of neonatal mice infected with CHIKV and WNV. Because autophagy dysregulation may underlie the pathogenesis of metabolic, inflammatory and neoplastic diseases (in addition to Similar results were observed in each independent experiment. *P , 0.05; **P , 0.01; ***P , 0.001; NS, not significant; t-test.
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its role in infections and neurodegenerative disorders), specific autophagy-inducing agents such as the Tat-beclin 1 peptide may have potential for the prevention and treatment of a broad range of human diseases.
METHODS SUMMARY
The active Tat-beclin 1 peptide sequence YGRKKRRQRRRGGTNVFNATFEIW HDGEFGT consisted of 11 amino acids from the Tat protein transduction domain attached via a G2 linker to modified beclin 1 amino acids 267-284. Tat-scrambled (YGRKKRRQRRRGGVGNDFFINHETTGFATEW) was used as a control peptide. Autophagy was measured using immunoblot assays (p62 degradation, LC3 conversion), detection of GFP-LC3 puncta with fluorescence microscopy, radiolabelled long-lived protein degradation, and electron microscopy. For in vitro experiments to measure the effects of Tat-beclin 1 peptide on the clearance of CFP-htt103Q protein, viral replication, or bacterial replication, cells were treated with 10 mM peptide for 2-4 h, except for the HIV-1 replication studies which used 0.5-5.0 mM peptide for 10 days. For in vivo experiments, GFP-LC3 transgenic C57/BL6J mice (for autophagy measurements) or nontransgenic C57/BL6J mice (for infections with CHIKV or WNV) were treated i.p. with 15-20 mg kg 21 of peptide.
Full Methods and any associated references are available in the online version of the paper.
METHODS
Cell culture. COS-7, HeLa, A549 and MCF7 cells were cultured in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. HBEC30-KT cells were cultured in keratinocyte-SFM with 50 mg ml 21 bovine pituitary extract, 5 ng ml 21 recombinant epidermal growth factor (Gibco) and 1% penicillin/streptomycin 28 . THP-1 and HCC827 cells were cultured in RPMI 1640 containing 10% FBS and 1% penicillin/streptomycin. For monocytic differentiation, THP-1 cells were incubated with 10 nM PMA (Sigma) for 72 h. MEFs were cultured in DMEM containing 15% FBS, 1% penicillin/streptomycin, 118 mM b-mercaptoethanol, and 13 MEM non-essential amino acids. HeLa/GFP-LC3 cells and HeLa-htt103Q cells have been described previously 13, 17 . Murine BMDMs were cultured in DMEM containing 20% heat-inactivated FBS, 20% L-cell supernatant, and 1% penicillin/streptomycin. Atg5 flox/flox and Atg5 flox/flox -LysM-Cre BMDMs have been described 19 . Primary human MDMs were prepared from whole blood and cultured in RPMI 1640 containing 10% charcoal/dextran-treated, heatinactivated FBS (Gemini Bio-Products) and 10 ng ml 21 macrophage CSF (R&D Systems) for 9 days as described 21 . Venous blood was obtained from HIV-1 seronegative subjects using a protocol approved by the Human Research Protections Program of the University of California, San Diego (Project 08-1613) in accordance with the Code of Federal Regulations on the Protection of Human Subjects (45 CFR part 46 and 21 CFR part 50 and 56). Written informed consent was obtained from blood donors before their participation. Plasmid construction and transfection. pCDNA3.1 Myc-Vps34 has been described previously 6 . BECN1 cDNA was subcloned from pCR3.1-beclin 1 (ref. 29) into pBICEP-CMV2 (Sigma). Truncated constructs of Flag-beclin 1 were subcloned as PCR products containing each domain into pBICEP-CMV2. Deletion constructs of Flag-beclin 1 and the Flag-beclin 1(H275E/S279D/ Q281E) mutant were generated by PCR mutagenesis and subcloned into pBICEP-CMV2. The HIV-1 SF2 Nef plasmid, pcDNA-Nef 30 , was provided by J. L. Foster. The Nef protein was fused with a 23 HA sequence at the C terminus by PCR and subcloned into pcDNA3.1. GAPR-1 cDNA from pCMV6-XL4 (Origene) was fused with a Myc sequence at the C terminus by PCR and subcloned into pcDNA3.1. Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Immunoprecipitation and fluorescent microscopy analysis were performed 20-27 h post-transfection. GFP-LC3 31 and mRFP-GFP-LC3 32 plasmids were provided by T. Yoshimori. Antibodies and reagents. For immunoblot analyses, rat monoclonal anti-HA (1:500 dilution, Roche), mouse monoclonal anti-Flag M2 (1:500 dilution, Sigma), mouse monoclonal anti-Myc (1:500 dilution, Santa Cruz), rabbit anti-LC3 (1:300 dilution, Novus Biologicals), mouse monoclonal anti-p62 (1:500 dilution, BD Biosciences), guinea-pig anti-p62 (1:500 dilution, Progen), mouse monoclonal anti-actin (1:2,000 dilution, Santa Cruz), rabbit anti-beclin 1 (1:1,000 dilution, Santa Cruz), rabbit anti-ATG7 (1:1,000 dilution, (Sigma), anti-ATG5 (1:500 dilution, Novus Biologicals), anti-GFP (1:500 dilution, Invitrogen) and rabbit anti-GAPR-1 (1:10,000 dilution) 14 were used. 3-MA (Sigma) was dissolved in H 2 O and used at a 10 mM concentration. Torin1 (gift from D. Sabatini) 33 , rapamcyin (Sigma) and bafilomycin A1 (Sigma) were dissolved in DMSO and used at concentrations of 1 mM, 500 nM and 100 nM, respectively. Immunoblot analyses. Cells were rinsed with Dulbecco's phosphate buffered saline (PBS(2), (Sigma)) and lysed in lysis buffer (20 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease inhibitor cocktail (Roche)) on ice for 1 h. Lysates were centrifuged at 16,100g for 10 min at 4 uC, and resolved by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% non-fat dry milk (NFDM) in PBST (PBS 0.05% Tween-20), incubated overnight at 4 uC with primary antibodies in PBST containing 5% NFDM, washed with PBST, and incubated for 1 h at room temperature with HRP-conjugated secondary antibodies diluted in PBST containing 5% NFDM. Immunoreactive bands were visualized with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) or Amersham ECL Plus Western Blotting Detection System (GE Healthcare).
For detection of beclin 1 and GAPR-1 in Golgi fractions of HeLa cells and HeLa/GAPR-1-Myc cells, Golgi-enriched fractions were isolated as described 34, 35 from cells treated with peptide (20 mM, 1 h), then trypsinized and homogenized with a Balch homogenizer (gap size 9 mm). Post-nuclear supernatant (PNS) was obtained after centrifugation of the cell homogenate (1,700 r.p.m., 10 min, 4 uC). The PNS was fractionated by sucrose density gradient ultracentrifugation (SV40 rotor at 100,000g, 2 h 40 min) and approximately 1 ml of a Golgi-enriched fraction was collected at the 35-29% sucrose interface. Membranes were pelleted by ultracentrifugation (100,000g, 30 min) after the addition of three volumes of PBS to one volume of Golgi-enriched fraction. Immunoprecipitation. Cell lysates were centrifuged at 16,100g for 10 min at 4 uC and the supernatants were subjected to immunoprecipitation with an anti-HA antibody (1:100 dilution, Roche) and protein G plus-agarose (Santa Cruz) or with anti-Myc agarose (1:20 dilution, Santa Cruz) and subjected to immunoblot analyses. Cell viability assays. Cytotoxicity was measured in HeLa cells using an LDH cytotoxicity kit (Cayman Chemical). Cytotoxicity in primary human MDMs was measured using WST-1 (Roche). Cell survival in primary murine BMDMs was measured by trypan blue exclusion or a CellTiter-Glo Luminescent Cell Viability assay kit (Promega). siRNA and shRNA suppression of gene expression. siRNAs were purchased from Thermo Scientific Dharmacon. siRNAs specific to BECN1 (59-GCACUC AAGUUCAUGCUUA-39), ATG7 (59-GGGUUAUUACUACAAUGGUGUU-39), C9orf19 (GAPR-1) (no. 2, 59-GCAAGAACCUCAACCGGGA-39 and no. 17, 59-GUUACCUAGACCACGAUUA-39) and a non-silencing control siRNA (NC-2) were transfected using Lipofectamine 2000. Immunoblot and fluorescent microscopic analyses were performed 48-72 h post-transfection. MISSION short-hairpin (shRNA) lentiviral particles were from Sigma: ATG5 (SHCLNV-NM_004849/ TRCN0000150940), or scrambled non-targeting negative control (Scr, SHC002V). Fluorescence microscopy and image analysis. For measurement of autophagy in HeLa/GFP-LC3 cells or MCF7 cells, cells were fixed with 2% paraformaldehyde (PFA) in PBS, and GFP-LC3-positive dots per cell was quantified as described 29 . To measure autophagic flux, HeLa cells were co-transfected with an mRFP-GFP-LC3 plasmid 32 and siRNA, treated with peptide (25 mM, 3 h) 72 h post-transfection, and then fixed as above. GFP-positive autophagosomes and RFP-positive autolysosomes per cell were quantified. For the htt103Q aggregate assay, CFP-positive aggregates ,1 mm were counted.
For immunofluorescence (IFA) analysis of cultured cells, HeLa cells were fixed as above, permeabilized in 0.5% Triton X-100/PBS, blocked with 0.5% BSA in PBS, stained with anti-WIPI2 15 (mouse, 1:500), anti-beclin 1 (rabbit, 1: 250, Santa Cruz), anti-GM130 (mouse, 1:250, Novus Biologicals), and labelled with goatanti-rabbit AlexaFluor 647 and goat-anti-mouse AlexaFluor 488 secondary antibodies (1:500) or stained with anti-streptavidin-AlexaFluor 488 (1:500) (after treatment with Tat-biotin-conjugated peptides). For the beclin 1 primary antibody, specificity was confirmed by siRNA knockdown. Z-stacks were acquired with a Zeiss AxioImager M2 microscope equipped with a Photometrics CoolSnap HQ2 camera using a Zeiss PLAN APO 20X/0.8 NA wide-field objective with the same acquisition times for samples stained with identical primary antibody pairs, then deconvolved with AutoDeBlur (Biotplane). Imaris version 7.4.0 (Bitplane) was used for analysis. Thresholding for background secondary antibody staining was performed in all experiments. Representative images were chosen after examining 60-120 cells from triplicate samples for each condition. Nuclear staining (besides DAPI) was masked using the DAPI channel and setting non-DAPI signal within the nuclear surface to zero. Quantification of WIPI2-positive dots per cell was performed by an observer blinded to experimental condition.
For IFA of mouse tissues, 5-day-old GFP-LC3 transgenic mice infected with CHIKV were treated with peptide (20 mg kg 21 , 6 h). Muscle sections were prepared as described in the section below, stained with an anti-CHIKV E2 antibody 13, 36 , and images were acquired as described for cultured cells above. For infrared (IR) dye images, muscle tissue was collected from peptide-treated GFP-LC3 mice (25 mg kg 21 i.p., 2 h), and sections were stained with streptavidin-conjugated IRDye 800CW (1:500 dilution; Licor). Images were acquired with a Zeiss AxioObserver Z1 microscope equipped with a Hamamatsu Orca II -ER camera using a Zeiss PLAN APO 633/1.4 NA oil objective and analysed by an observer blinded to experimental condition. Electron microscopy. HeLa cells were fixed overnight with 2.5% glutaraldehyde in 0.1 M (pH 7.4) cacodylate buffer and samples were prepared and analysed as described 8 . Immunohistochemistry. Mouse brain sections were fixed in 4% PFA. Paraffinembedded sagittal sections were TUNEL-stained to detect apoptotic nuclei (Apoptag peroxidase in situ Apoptosis Detection Kit; Chemicon International). Immunoperoxidase staining was performed to detect WNV antigen (rat polyclonal anti-WNV antibody; 1:100 dilution; provided by M. Diamond). Peptide design. An evolutionary trace (ET) analysis 37 revealed regions within the 267-299 domain of beclin 1 likely to be of evolutionary importance. To enhance the solubility of the Tat PTD (amino acids 47-57) 10 fused to the beclin 1 267-284 fragment, ET analysis of beclin 1 further identified residue positions unlikely to be functionally important occupied by charged residues in beclin 1 orthologues. These cognate residues were then substituted into the peptide (H275E, S79D and Q281E) to increase its solubility without disrupting its mimicry of beclin 1 function. Peptide synthesis. L-amino acid peptides were synthesized by the University of Texas Southwestern Medical Center (UTSW) Protein Chemistry Technology Core and purified to .95% by HPLC (confirmed by mass spectrometry). The Tat-beclin 1 peptide sequence, YGRKKRRQRRRGGTNVFNATFEIWHDG EFGT, consisted of 11 amino acids from the Tat PTD at the N terminus, a GG ARTICLE RESEARCH
